324 related articles for article (PubMed ID: 21677353)
1. [Metformin - mechanisms of action and use for the treatment of type 2 diabetes mellitus].
Grzybowska M; Bober J; Olszewska M
Postepy Hig Med Dosw (Online); 2011 May; 65():277-85. PubMed ID: 21677353
[TBL] [Abstract][Full Text] [Related]
2. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study.
Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH
J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983
[TBL] [Abstract][Full Text] [Related]
3. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
Tarasova L; Kalnina I; Geldnere K; Bumbure A; Ritenberga R; Nikitina-Zake L; Fridmanis D; Vaivade I; Pirags V; Klovins J
Pharmacogenet Genomics; 2012 Sep; 22(9):659-66. PubMed ID: 22735389
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic variation and metformin response.
Chen S; Zhou J; Xi M; Jia Y; Wong Y; Zhao J; Ding L; Zhang J; Wen A
Curr Drug Metab; 2013 Dec; 14(10):1070-82. PubMed ID: 24329113
[TBL] [Abstract][Full Text] [Related]
5. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.
Shu Y; Sheardown SA; Brown C; Owen RP; Zhang S; Castro RA; Ianculescu AG; Yue L; Lo JC; Burchard EG; Brett CM; Giacomini KM
J Clin Invest; 2007 May; 117(5):1422-31. PubMed ID: 17476361
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of metformin.
Graham GG; Punt J; Arora M; Day RO; Doogue MP; Duong JK; Furlong TJ; Greenfield JR; Greenup LC; Kirkpatrick CM; Ray JE; Timmins P; Williams KM
Clin Pharmacokinet; 2011 Feb; 50(2):81-98. PubMed ID: 21241070
[TBL] [Abstract][Full Text] [Related]
7. [Molecular action of insulin-sensitizing agents].
Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
[TBL] [Abstract][Full Text] [Related]
8. Metformin as an Anticancer Agent.
Vancura A; Bu P; Bhagwat M; Zeng J; Vancurova I
Trends Pharmacol Sci; 2018 Oct; 39(10):867-878. PubMed ID: 30150001
[TBL] [Abstract][Full Text] [Related]
9. Diabetes medication associates with DNA methylation of metformin transporter genes in the human liver.
García-Calzón S; Perfilyev A; Männistö V; de Mello VD; Nilsson E; Pihlajamäki J; Ling C
Clin Epigenetics; 2017; 9():102. PubMed ID: 28947922
[TBL] [Abstract][Full Text] [Related]
10. The influence of metformin transporter gene SLC22A1 and SLC47A1 variants on steady-state pharmacokinetics and glycemic response.
Ningrum VDA; Sadewa AH; Ikawati Z; Yuliwulandari R; Ikhsan MR; Fajriyah R
PLoS One; 2022; 17(7):e0271410. PubMed ID: 35905099
[TBL] [Abstract][Full Text] [Related]
11. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients.
Umamaheswaran G; Praveen RG; Damodaran SE; Das AK; Adithan C
Clin Exp Med; 2015 Nov; 15(4):511-7. PubMed ID: 25492374
[TBL] [Abstract][Full Text] [Related]
12. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Diabetes; 2009 Mar; 58(3):745-9. PubMed ID: 19228809
[TBL] [Abstract][Full Text] [Related]
13. Role of human organic cation transporter-1 (OCT-1/SLC22A1) in modulating the response to metformin in patients with type 2 diabetes.
Kawoosa F; Shah ZA; Masoodi SR; Amin A; Rasool R; Fazili KM; Dar AH; Lone A; Ul Bashir S
BMC Endocr Disord; 2022 May; 22(1):140. PubMed ID: 35619086
[TBL] [Abstract][Full Text] [Related]
14. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus.
Foretz M; Guigas B; Viollet B
Nat Rev Endocrinol; 2019 Oct; 15(10):569-589. PubMed ID: 31439934
[TBL] [Abstract][Full Text] [Related]
15. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacogenet Genomics; 2010 Jan; 20(1):38-44. PubMed ID: 19898263
[TBL] [Abstract][Full Text] [Related]
16. Bright renoprotective properties of metformin: beyond blood glucose regulatory effects.
Nasri H; Baradaran A; Ardalan MR; Mardani S; Momeni A; Rafieian-Kopaei M
Iran J Kidney Dis; 2013 Nov; 7(6):423-8. PubMed ID: 24241085
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes.
Tkáč I; Klimčáková L; Javorský M; Fabianová M; Schroner Z; Hermanová H; Babjaková E; Tkáčová R
Diabetes Obes Metab; 2013 Feb; 15(2):189-91. PubMed ID: 22882994
[TBL] [Abstract][Full Text] [Related]
18. Is Metformin a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics.
Markowicz-Piasecka M; Huttunen KM; Mateusiak L; Mikiciuk-Olasik E; Sikora J
Curr Pharm Des; 2017; 23(17):2532-2550. PubMed ID: 27908266
[TBL] [Abstract][Full Text] [Related]
19. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.
Shikata E; Yamamoto R; Takane H; Shigemasa C; Ikeda T; Otsubo K; Ieiri I
J Hum Genet; 2007; 52(2):117-122. PubMed ID: 17111267
[TBL] [Abstract][Full Text] [Related]
20. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.
Guppy A; Jamal-Hanjani M; Pickering L
Future Oncol; 2011 Jun; 7(6):727-36. PubMed ID: 21675836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
